@misc{oai:repo.qst.go.jp:00070510,
 author = {Sugyou, Aya and Tsuji, Atsushi and Sudou, Hitomi and Yoshida, Chisato and Kurosawa, Yoshikazu and Saga, Tsuneo and et.al and 須尭 綾 and 辻 厚至 and 須藤 仁美 and 吉田 千里 and 黒澤 良和 and 佐賀 恒夫},
 month = {Sep},
 note = {We radiolabeled the antibody with 125I by the chloramine-T method, and with 67Ga or 89Zr using deferoxamine. We conducted in vitro cell binding and competitive inhibition assays using a human pancreatic carcinoma cell line, MIAPaCa-2, which highly expressed TfR and a mouse fibroblast cell line A4, which highly expressed human HER2 but not human TfR. We inoculated MIAPaCa-2 and A4 cells subcutaneously into each side of hind limb and conducted PET imaging from one to six days postinjection of the 89Zr-labeled antibody. The cell binding assay showed that radiolabeled antibodies specifically bound to MIAPaCa-2 cells, but not to A4 cells. The Bmax of 125I-, 67Ga- and 89Zr-labeled antibodies was 69, 86 and 64 %, respectively. The competitive inhibition assay showed that Kd of 125I-labeled antibodies was 2 nM, respectively. Temporal PET imaging with the 89Zr -labeled antibody showed that the MIAPaca-2 tumor was readily visualized on day 1 postinjection and became clearer thereafter, and the uptake in the MIAPaca-2 tumor increased with time and reached 24.8% of injected dose per gram on day 6, whereas that in the A4 tumor was low and decreased with time. In conclusion, the radiolabeled anti-TfR antibody could be applicable for TfR-specific PET imaging and help in selecting appropriate patients for TfR-targeted treatments., 14th International Congress of Radiation Research(ICRR’2011)},
 title = {Tumor-specific imaging with radiolabeled human anti-transferrin receptor antibody in pancreatic cancer mouse model},
 year = {2011}
}